Drug Pricing
14 articles on Drug Pricing, written by Shotlee and medically reviewed for clinical accuracy.
Supreme Court Ruling: Medicare Drug Price Negotiations Move Forward
In a significant victory for healthcare cost containment, the Supreme Court has allowed Medicare to proceed with negotiating drug prices. This decision upholds a key provision of the Inflation Reduction Act and could impact the cost of many prescription medications, including widely used GLP-1 agonists.
6 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
6 min read
Why Ozempic & GLP-1s Cost More in the US: A Guide
A 54-year-old father walked away from his $997 Ozempic prescription due to sky-high costs. GLP-1 medications like Ozempic and Mounjaro offer transformative benefits for diabetes and obesity, yet US prices make them unaffordable for millions. This guide breaks down the pricing crisis, clinical value, and paths to reform.
4 min read
Calgary Doctor Claims Generic Ozempic and Wegovy Drugs May Cut Costs by One-Third
According to a Calgary doctor, affordable generic alternatives to drugs like Ozempic and Wegovy might reduce expenses by up to a third. The content explores regional approaches to obesity management in Canada, emphasizing the challenges of rewiring brain circuitry and the role of medications in promoting healthier eating habits.
1 min read
Novo Nordisk Cuts Wegovy Price in China Ahead of Patent Expiration Amid Growing Copycats
Novo Nordisk has lowered the cost of its obesity treatment Wegovy in China in anticipation of patent expiration and rising generic competitors. The price reduction aims to ease patient treatment burdens, as reported in regional drug procurement data. This move also reflects changes on major online marketplaces, allowing nationwide ordering after doctor consultations.
2 min read
Novo Nordisk Receives US Approval for Oral GLP-1 Weight-Loss Medication
The FDA has approved Novo Nordisk's Wegovy as an oral medication for weight loss. This provides an alternative to injections for adults with obesity or weight-related health issues. The company anticipates a US launch in January.
2 min read
Novo Nordisk Introduces Ozempic in India for Type 2 Diabetes, Prices Aligned to Wegovy
Novo Nordisk has launched Ozempic in India, an injectable semaglutide treatment intended for type 2 diabetes. The company is positioning the drug alongside its obesity medication, Wegovy. Pricing will be similar to Wegovy.
2 min read
Novo Nordisk India's Vikrant Shrotriya on Ensuring Ozempic Supply
Vikrant Shrotriya of Novo Nordisk India details Ozempic's launch in India, emphasizing stable supply and accessibility. He addresses patent expiry and competition, focusing on broader patient access and combating obesity.
6 min read
Generic Drug Manufacturers Eye Price Adjustments as Novo Reduces Wegovy Costs
Following Novo Nordisk's price reduction for its Wegovy injection, generic drug manufacturers are reassessing their pricing strategies. The move comes amid increasing competition in the weight-loss drug market, with potential impacts on affordability and market share.
3 min read
Medicare Achieves 71% Discount on Novo's Ozempic and Wegovy
The U.S. government has successfully negotiated a 71% discount on Novo Nordisk's popular drugs Ozempic and Wegovy for Medicare beneficiaries. These price reductions, resulting from recent legislation, will be implemented in 2027, potentially saving millions of dollars.
5 min read
Indian Drugmakers Adjust GLP-1 Pricing as Novo Nordisk Reduces Wegovy Cost in India
Indian drugmakers are modifying their pricing strategies for weight-loss injections after Novo Nordisk decreased the price of Wegovy. Generic companies are now reassessing their launch prices due to this shift. Competition is anticipated to lower prices in the GLP-1 market.
3 min read
Novo Nordisk Introduces $199 Introductory Deal for Wegovy and Ozempic Before Anticipated Price Reductions
Novo Nordisk is launching a special promotion, offering Wegovy and Ozempic at $199 per month for new self-pay patients. This introductory offer is available until March 31, 2026, and is valid for the initial two months of therapy at the lowest dosages.
3 min read
Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
2 min read